Literature DB >> 30506167

Methodological Concerns of a Recent Network Meta-analysis Assessing Biologics for Eosinophilic Asthma.

N B Gunsoy1, D J Bratton2, R Alfonso-Cristancho3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30506167     DOI： 10.1007/s00408-018-0183-x

Source DB:  PubMed          Journal:  Lung        ISSN： 0341-2040            Impact factor:   2.584


× No keyword cloud information.
  4 in total

1.  Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.

Authors:  Mario Castro; James Zangrilli; Michael E Wechsler; Eric D Bateman; Guy G Brusselle; Philip Bardin; Kevin Murphy; Jorge F Maspero; Christopher O'Brien; Stephanie Korn
Journal:  Lancet Respir Med       Date:  2015-02-23       Impact factor: 30.700

2.  Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.

Authors:  Geoffrey L Chupp; Eric S Bradford; Frank C Albers; Daniel J Bratton; Jie Wang-Jairaj; Linda M Nelsen; Jennifer L Trevor; Antoine Magnan; Anneke Ten Brinke
Journal:  Lancet Respir Med       Date:  2017-04-05       Impact factor: 30.700

3.  Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.

Authors:  Imran H Iftikhar; Mathew Schimmel; William Bender; Colin Swenson; David Amrol
Journal:  Lung       Date:  2018-08-23       Impact factor: 2.584

4.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

Authors:  Elisabeth H Bel; Sally E Wenzel; Philip J Thompson; Charlene M Prazma; Oliver N Keene; Steven W Yancey; Hector G Ortega; Ian D Pavord
Journal:  N Engl J Med       Date:  2014-09-08       Impact factor: 91.245
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.